This review summarizes the role of histone deacetylase inhibitors (HDACi) as epigenetic anti-cancer therapy and evidence that class I selective HDACi, particularly those biased to HDAC3 may be a promising therapeutic strategy for ovarian cancer. This evidence concerns the gene HDAC3 and ovarian cancer.